Growth rate-corrected (GR) dose-response metric signatures across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 3 of 4: Median, upper quartile, and lower quartile GR metrics per perturbagen. - Dataset - HMS LINCS Database

Growth rate-corrected (GR) dose-response metric signatures across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 3 of 4: Median, upper quartile, and lower quartile GR metrics per perturbagen. - Dataset (ID:20270)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Antibodies

<
<<
Previous
Page 1 of 4
Next
>>
>
1 to 25 of 90 records
per page:

Small Molecule	Antibody	Perturbagen Target	Perturbagen Class	GR50 lower quartile	GR50 median	GR50 upper quartile	GRmax lower quartile	GRmax median	GRmax upper quartile	GRinf lower quartile	GRinf median	GRinf upper quartile	Hill Coefficient lower quartile	Hill Coefficient median	Hill Coefficient upper quartile	GR_AOC lower quartile	GR_AOC median	GR_AOC upper quartile	GEC50 lower quartile	GEC50 median	GEC50 upper quartile
FTase Inhibitor I		Ftase	MAPK	100.0000	100.0000	100.0000	0.7715	0.8851	0.9752	0.7468	0.8851	0.9752	0.0000	0.0000	0.0000	0.0099	0.0556	0.0941	100.0000	100.0000	100.0000
Dichloroacetate		PDK	PDK	100.0000	100.0000	100.0000	0.8082	0.8801	0.9216	0.7946	0.8670	0.9296	0.0000	0.0000	0.2064	0.0234	0.0440	0.0744	58.3872	100.0000	100.0000
PD184352		MEK	MAPK	31.0822	100.0000	100.0000	0.4258	0.7584	0.9084	-0.2272	0.7139	0.9084	0.0000	0.0524	0.4766	0.0368	0.0888	0.1432	63.7076	100.0000	100.0000
Torkinib		MTOR	MTOR	0.0008	0.0021	0.0184	-0.5713	-0.3826	-0.2014	-0.6715	-0.4047	-0.1504	0.3324	0.3720	0.5454	0.6694	0.8411	1.0104	0.0046	0.0211	0.0646
5-DFUR		TYMS	TYMS	68.5295	100.0000	100.0000	-0.1871	-0.0208	0.0399	-0.5625	-0.3158	-0.1425	0.3943	0.5084	0.6195	0.2584	0.3100	0.3856	100.0000	100.0000	100.0000
Nilotinib		ABL	nRTK	100.0000	100.0000	100.0000	0.7849	0.9109	1.0055	0.7841	0.9109	1.0055	0.0000	0.0000	0.7234	0.0029	0.0487	0.0775	73.6076	100.0000	100.0000
Everolimus		MTOR	MTOR	0.0432	0.6717	4.3873	-0.8294	-0.6714	-0.2303	-1.0000	-1.0000	-0.6838	0.2890	0.4230	0.7677	0.3295	0.4415	0.5925	1.5205	9.7227	26.2255
PD 98059		MEK	MAPK	100.0000	100.0000	100.0000	0.5235	0.6650	0.8191	-0.1517	0.5395	0.8149	0.0000	0.2473	0.7779	0.0463	0.0842	0.1501	32.4005	100.0000	100.0000
5-FU		TYMS	TYMS	43.5628	98.8715	100.0000	-0.6126	-0.4736	-0.0711	-0.8532	-0.6532	-0.1200	0.5225	0.5967	0.7832	0.3295	0.4853	0.6100	100.0000	100.0000	100.0000
	Cetuximab	EGFR	ErbB	100.0000	100.0000	100.0000	0.7284	0.8755	0.9754	0.5964	0.8555	0.9754	0.0000	0.0000	0.7916	-0.0099	0.0234	0.0674	3.7461	100.0000	100.0000
PS-1145		IKK	NFKB	100.0000	100.0000	100.0000	0.8452	0.9304	0.9718	0.8353	0.9304	0.9695	0.0000	0.0000	0.8067	-0.0033	0.0200	0.0533	100.0000	100.0000	100.0000
Selumetinib		MEK	MAPK	3.4703	100.0000	100.0000	0.2888	0.6993	0.8618	0.1384	0.6524	0.8687	0.0000	0.4990	0.9393	0.0510	0.1233	0.3040	0.3246	2.6951	100.0000
Omipalisib		PI3K	PI3K	0.0049	0.0154	0.0397	-0.8281	-0.5752	-0.4164	-0.8004	-0.5070	-0.2908	0.6200	0.7592	0.9464	0.6332	0.8101	0.9689	0.0158	0.0370	0.0945
Triciribine		AKT	AKT	0.1497	1.0069	10.2321	-0.2208	0.0730	0.3595	-0.6783	-0.3270	0.0049	0.3693	0.5173	0.9769	0.1961	0.3180	0.4712	0.2958	1.3169	18.2553
Ribavirin		N/A	N/A	100.0000	100.0000	100.0000	0.6045	0.7146	0.9546	0.4725	0.6701	0.9546	0.0000	0.0000	0.9838	0.0119	0.0416	0.0703	50.4745	100.0000	100.0000
Oxaliplatin		DNA cross-linker	DNA cross-linker	3.2681	4.9333	12.0662	-0.9391	-0.8084	-0.7104	-1.0000	-1.0000	-0.9516	0.6228	0.7486	1.0057	0.4005	0.5419	0.5768	14.7918	22.6957	42.6124
Temsirolimus		MTOR	MTOR	0.1192	1.7003	10.0307	-0.9332	-0.8176	-0.6679	-1.0000	-1.0000	-0.9967	0.2520	0.4363	1.0813	0.3951	0.4933	0.6311	6.4751	18.8586	43.0334
Sirolimus		MTOR	MTOR	0.0785	2.7199	100.0000	-0.0907	0.1172	0.3521	-0.3854	0.0690	0.4042	0.2746	0.5743	1.0909	0.2471	0.4095	0.5054	0.0261	0.5698	12.7823
Topotecan		TOP1	TOP	0.0324	0.1223	0.4672	-0.7615	-0.5906	-0.2740	-0.8265	-0.6901	-0.4582	0.5573	0.7931	1.1373	0.5801	0.7088	0.8375	0.0774	0.7078	1.2170
CGC-11047		Polyamine analogue	N/A	43.1451	85.4630	100.0000	-0.8722	-0.7234	-0.2437	-1.0000	-0.9172	-0.4365	0.4134	0.5735	1.1488	0.3172	0.3971	0.4905	94.6485	100.0000	100.0000
Etoposide		TOP2	TOP	1.1610	2.9708	7.6285	-0.6938	-0.4841	-0.2079	-0.7406	-0.5842	-0.4690	0.5531	0.8108	1.2247	0.3770	0.4769	0.5711	4.4274	7.6731	19.6965
Lapatinib		EGFR/HER2	ErbB	31.2806	100.0000	100.0000	0.4954	0.7950	0.9113	0.2428	0.7519	0.9066	0.0000	0.2457	1.3492	0.0247	0.0703	0.1302	1.5972	63.5403	100.0000
Tozasertib		AURK/FLT3/ABL/JAK2	AURK	0.9523	4.3787	11.8540	-0.5661	-0.3376	-0.0359	-1.0000	-1.0000	-0.4350	0.4858	0.8218	1.3502	0.1794	0.3014	0.3656	4.7346	16.5294	34.8041
Pevonedistat		NAE1	NAE1	0.1439	0.3445	1.2615	-0.3074	-0.0880	0.0407	-0.4612	-0.1540	0.0480	0.6476	0.9529	1.4328	0.3433	0.4344	0.5442	0.1672	0.7014	1.4696
Lestaurtinib		FLT3/JAK2/TrkA	RTK	0.2491	0.7096	1.5478	-0.9565	-0.8762	-0.7290	-1.0000	-1.0000	-0.9202	0.6212	0.8572	1.4388	0.3615	0.4228	0.5481	1.3258	2.5025	5.3389

<
<<
Previous
Page 1 of 4
Next
>>
>
1 to 25 of 90 records
per page:

HMS LINCS Project

Growth rate-corrected (GR) dose-response metric signatures across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 3 of 4: Median, upper quartile, and lower quartile GR metrics per perturbagen. - Dataset (ID:20270)